PMID- 17284082
OWN - NLM
STAT- MEDLINE
DCOM- 20070501
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 67
IP  - 2
DP  - 2007
TI  - Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.
PG  - 155-74
AB  - A synergy between HIV type-1 (HIV-1) and herpes simplex virus-2 (HSV-2) has been 
      demonstrated in many epidemiological and clinical studies over the last decade. 
      HIV-1 infection exacerbates the clinical impact and frequency of HSV-2 
      reactivation events; furthermore, HSV-2 infection exacerbates the risk of HIV 
      acquisition and transmission and may accentuate HIV disease progression. In order 
      to maximise the impact of existing and future therapeutic and preventive 
      interventions, this article reviews the epidemiological, clinical and therapeutic 
      considerations associated with episodic treatment and suppression of HSV-2 
      infection in HIV-infected individuals.Specifically, this article describes the 
      current expanding epidemics of both HIV and HSV-2, and how high rates of 
      asymptomatic herpes virus shedding contribute to the under-diagnosis and 
      continued spread of both HSV-2 and HIV. Furthermore, multiple clinical trials 
      have studied the efficacy and clinical utility of aciclovir and other nucleoside 
      analogues for treating and suppressing HSV-2. We review these studies and 
      summarise the guidelines for these regimens, particularly noting the accumulated 
      experience documenting the utility of herpes treatment and suppression in 
      altering the natural history of symptoms and documenting the low rate of HSV-2 
      drug resistance to nucleoside analogues observed after more that a decade of use. 
      Finally, there are now also growing data describing the benefits of herpes 
      suppression in the context of individuals co-infected with HIV/HSV-2, with 
      additional clinical trials poised to further elucidate these issues in the near 
      future.
FAU - Lingappa, Jairam R
AU  - Lingappa JR
AD  - Department of Medicine, University of Washington, Seattle, USA. 
      lingappa@u.washington.edu
FAU - Celum, Connie
AU  - Celum C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antiviral Agents)
SB  - IM
EIN - Drugs. 2007;67(8):1147
MH  - Antiviral Agents/administration & dosage/*therapeutic use
MH  - *Drug Resistance, Viral
MH  - Female
MH  - HIV Infections/complications/*drug therapy/epidemiology
MH  - Herpes Genitalis/complications/*drug therapy/epidemiology
MH  - Humans
MH  - Male
MH  - Virus Shedding
RF  - 178
EDAT- 2007/02/08 09:00
MHDA- 2007/05/02 09:00
CRDT- 2007/02/08 09:00
PHST- 2007/02/08 09:00 [pubmed]
PHST- 2007/05/02 09:00 [medline]
PHST- 2007/02/08 09:00 [entrez]
AID - 6721 [pii]
AID - 10.2165/00003495-200767020-00001 [doi]
PST - ppublish
SO  - Drugs. 2007;67(2):155-74. doi: 10.2165/00003495-200767020-00001.